Guan SW, Lin Q, Yu HB. Intratumour microbiome of pancreatic cancer. World J Gastrointest Oncol 2023; 15(5): 713-730 [PMID: 37275446 DOI: 10.4251/wjgo.v15.i5.713]
Corresponding Author of This Article
Hai-Bo Yu, MD, Chief Doctor, Department of Surgery, Wenzhou Central Hospital, The Dingli Clinical Institute of Wenzhou Medical University, No. 252 Baili East Road, Wenzhou 325000, Zhejiang Province, China. yuhaibozjwz@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. May 15, 2023; 15(5): 713-730 Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.713
Intratumour microbiome of pancreatic cancer
Shi-Wei Guan, Quan Lin, Hai-Bo Yu
Shi-Wei Guan, Quan Lin, Hai-Bo Yu, Department of Surgery, Wenzhou Central Hospital, The Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Author contributions: All authors contributed to the original ideas and writing of this paper; Guan SW wrote the paper; Lin Q draw figures; Yu HB made critical revisions of this paper; all authors have read and approve the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Bo Yu, MD, Chief Doctor, Department of Surgery, Wenzhou Central Hospital, The Dingli Clinical Institute of Wenzhou Medical University, No. 252 Baili East Road, Wenzhou 325000, Zhejiang Province, China. yuhaibozjwz@163.com
Received: December 2, 2022 Peer-review started: December 2, 2022 First decision: January 16, 2023 Revised: January 26, 2023 Accepted: April 4, 2023 Article in press: April 4, 2023 Published online: May 15, 2023 Processing time: 160 Days and 21.5 Hours
Abstract
Pancreatic cancer is a high mortality malignancy with almost equal mortality and morbidity rates. Both normal and tumour tissues of the pancreas were previously considered sterile. In recent years, with the development of technologies for high-throughput sequencing, a variety of studies have revealed that pancreatic cancer tissues contain small amounts of bacteria and fungi. The intratumour microbiome is being revealed as an influential contributor to carcinogenesis. The intratumour microbiome has been identified as a crucial factor for pancreatic cancer progression, diagnosis, and treatment, chemotherapy resistance, and immune response. A better understanding of the biology of the intratumour microbiome of pancreatic cancer contributes to the establishment of better early cancer screening and treatment strategies. This review focuses on the possible origins of the intratumour microbiome in pancreatic cancer, the intratumour localization, the interaction with the tumour microenvironment, and strategies for improving the outcome of pancreatic cancer treatment. Thus, this review offers new perspectives for improving the prognosis of pancreatic cancer.
Core Tip: Recently, with the development of high-throughput sequencing, tumour tissues, which were previously believed to be sterile, have been shown to harbor a low microbiome biomass. The intratumour microbiome is crucial for pancreatic ductal adenocarcinoma (PDAC) diagnosis, treatment, chemotherapy resistance, and immune response. Establishing an awareness of the biology of the tumour microbiome in PDAC supports the establishment of better strategies for PDAC. This review focuses on the possible origins of the microbiome, the localization, the interaction with the tumour microenvironment and the strategies for improving the outcomes of treatment. This review offers new perspectives for improving the prognosis of PDAC.
